InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.87
(
-0.53%
)
Bitcoin
54,403.34
(
-4.52%
)
Post# of 252486
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 82738

Saturday, 08/22/2009 12:36:40 PM

Saturday, August 22, 2009 12:36:40 PM

Post# of 252486
MELA – Building on your comments, I find it notable that the plug in today’s Barron’s mentions the test’s specificity but not its sensitivity.

Seasoned biotech investors know that a diagnostic for the general public isn’t worth a dime unless both the sensitivity and the specificity are sky-high.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up